Distribution and molecular characterization of hepatitis C virus (HCV) genotypes in patients with chronic infection from Pernambuco State, Brazil

Alvarado-Mora, Mónica Viviana; Moura, Izolda; Botelho-Lima, Lívia; Azevedo, Raymundo Soares; Lopes, Edmundo Pessoa; Carrilho, Flair José; Pinho, J R R

doi:10.1016/j.virusres.2012.06.023

Cited by 7 publications

(10 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Com relação aos genótipos, o tipo 1 foi o mais frequente, com 77,10%, seguido do genótipo 3, com 19,84%. Essa frequência já foi encontrada em diversos locais do País, como demonstrado pelos estudos de Araújo et al 21 , em Manaus, estado do Amazonas; de Alvarado-Mora et al 27 , no estado do Pernambuco; de Oliveira et al 20 , no interior do estado de Minas Gerais; e de Paraboni et al 8 28 , os países da América Latina apresentam prevalência estimada de 1,4% HCV, com taxa virêmica de hepatite C de 76,4%. O genótipo mais representativo é o tipo 1 (74,3%), seguido do 3 (14,2%) e do 2 (10,4%), havendo baixa soroprevalência de casos pelos genótipos 4 e 5.…”

Section: Discussionunclassified

See 1 more Smart Citation

Perfil epidemiológico dos casos de hepatite C em um hospital de referência em doenças infectocontagiosas no estado de Goiás, Brasil

Oliveira

Reis

Barreto

et al. 2018

Revista Pan-Amazônica de Saúde

View full text Add to dashboard Cite

, no período de 2012 a 2015. MATERIAIS E MÉTODOS: Estudo epidemiológico transversal, realizado a partir dos casos notificados e confirmados de hepatites virais obtidos do Sistema de Informação de Agravos de Notificação. Os dados foram tabulados no programa TabWin e analisados no Epi Info™. O teste estatístico utilizado foi o Qui-quadradro. RESULTADOS: Dos 293 casos de hepatite C confirmados, a média de idade foi de 50,7 anos (DP ± 12,4), sendo que 54,95% ocorreram no sexo masculino, com predomínio da raça parda (75,09%). Quanto à escolaridade, 34,81% possuíam entre cinco e nove anos de estudo. A proporção dos genótipos encontrados foi de 77,10% para o tipo 1, 1,53% para o tipo 2, 19,84% para o tipo 3 e 1,53% para o tipo 4. Quanto às condições de saúde, verificou-se associação significativa na coinfecção entre o vírus da hepatite C (HCV) e o HIV (p < 0,001). CONCLUSÃO: Neste estudo, o perfil encontrado para os portadores de HCV foi semelhante aos disponíveis na literatura. Ressalta-se a importância de conhecer a frequência do HCV para compreender sua disseminação e, assim, ter subsídios para medidas de controle no combate à infecção, visto que a hepatite C é um problema de saúde pública.

show abstract

Section: Discussionunclassified

“…No presente estudo, os genótipos 2 e 4 apresentaram frequências de 1,53% cada. Essa baixa proporção também foi relatada em outros estudos 11,27 . Entretanto, essa frequência está abaixo da encontrada nos estudos de Oliveira et al 20 e de Paraboni et al 8 .…”

Section: Discussionunclassified

Perfil epidemiológico dos casos de hepatite C em um hospital de referência em doenças infectocontagiosas no estado de Goiás, Brasil

Oliveira

Reis

Barreto

et al. 2018

Revista Pan-Amazônica de Saúde

View full text Add to dashboard Cite

show abstract

“…Chronic HCV can lead to complications like cirrhosis and hepatocellular carcinoma (HCC), which are the main reasons for liver transplantation [2]. There are three million people infected with HCV in Brazil, with regional differences in the infection rates observed across the country [3]; these differences range from 0.28% in central and western regions to 0.62% in the north. According to the National Information System on Disease Notification (SINAN) of the Brazilian Ministry of Health, between 1999 and 2009, 60,908 new cases of hepatitis C were recorded [4].…”

Section: Introductionmentioning

confidence: 99%

“…Lower response rates are found in individuals infected with the HCV genotype 1, the most common genotype worldwide [5]. In Brazil, some studies have described the prevalence of genotype 1 [3,6,7]. Hence, many direct-acting antiviral compounds are being considered for anti-HCV therapy [8].…”

Section: Introductionmentioning

confidence: 99%

Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study

Hoffmann

Ramos

Souza

et al. 2013

Virol J

View full text Add to dashboard Cite

About sixty thousand new cases of Hepatitis C virus (HCV) infection are recorded in Brazil each year. These cases are currently treated with pegylated interferon (PEG-IFN) and ribavirin (RBV) with an overall success rate of 50%. New compounds for anti-HCV therapy targeted to the HCV NS3 protease are being developed and some already form the components of licensed therapies. Mapping NS3 protease resistance mutations to protease inhibitors or anti-viral drug candidates is important to direct anti-HCV drug treatment.MethodsSequence analysis of the HCV NS3 protease was conducted in a group of 68 chronically infected patients harboring the HCV genotype 1. The patients were sampled before, during and after a course of PEG-IFN-RBV treatment.ResultsResistance mutations to the protease inhibitors, Boceprevir and Telaprevir were identified in HCV isolated from three patients (4.4%); the viral sequences contained at least one of the following mutations: V36L, T54S and V55A. In one sustained virological responder, the T54S mutation appeared during the course of PEG-IFN and RBV therapy. In contrast, V36L and V55A mutations were identified in virus isolated from one relapsing patient before, during, and after treatment, whereas the T54S mutation was identified in virus isolated from one non-responding patient, before and during the treatment course.ConclusionsThe incidence and persistence of protease resistance mutations occurring in HCV from chronically infected patients in Brazil should be considered when using protease inhibitors to treat HCV disease. In addition, patients treated with the current therapy (PEG-IFN and RBV) that are relapsing or are non-responders should be considered candidates for protease inhibitor therapy.

show abstract

“…Chronic hepatitis C (CHC) was the third leading cause of liver transplantation in the United States of America (USA) in 2017, and over the last 15 years, it has accounted for 54% of indications for liver transplantation due to cirrhosis in Europe 2 . In Brazil, in 2019, it has been estimated that 22,747 thousand people were infected with HCV 3 , with genotypes 1 and 3 being the most frequent 4 , and these genotypes are also predominant in Northeast Brazil 5 . Between 2000 and 2015, CHC accounted for more than 70% of the 46,314 deaths caused by viral hepatitis in Brazil 6 .…”

Section: Introductionmentioning

confidence: 99%

A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil

Silva

Batista

Lopes

et al. 2021

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

show abstract

Distribution and molecular characterization of hepatitis C virus (HCV) genotypes in patients with chronic infection from Pernambuco State, Brazil

Cited by 7 publications

References 36 publications

Perfil epidemiológico dos casos de hepatite C em um hospital de referência em doenças infectocontagiosas no estado de Goiás, Brasil

Perfil epidemiológico dos casos de hepatite C em um hospital de referência em doenças infectocontagiosas no estado de Goiás, Brasil

Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study

A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil

Contact Info

Product

Resources

About